Exclusively focused on translational aspects of drug delivery, this journal provides a unique forum for publication of high-quality research.

Drug Delivery and Translational Research publishes research focused on such topics as designing and developing novel drug delivery systems, with a focus on their application to disease conditions; preclinical and clinical data related to drug delivery systems; short-term and long-term biocompatibility of drug delivery systems, host response; biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering; image-guided drug therapy; nanomedicine; devices for drug delivery and drug/device combination products.

In addition to original full-length papers, communications, and reviews, the journal includes editorials, reports of future meetings, research highlights, and announcements pertaining to activities of the Controlled Release Society.

Drug Delivery and Translational Research publishes six issues a year.

  • Accepted by ISI in SCIE, Biosis Previews and Biological Abstracts

    Explores the effect in different disease conditions of rationally developed, effective delivery systems
  • Focuses on high-quality research on the development of novel drug delivery systems
  • Presents full-length papers, communications, and reviews, editorials and more

Journal information

Editor-in-Chief
  • Maria Jose Alonso
Publishing model
Hybrid. Open Access options available

Journal metrics

3.111 (2018)
Impact factor
3.345 (2018)
Five year impact factor
37 days
Submission to first decision
113 days
Submission to acceptance
87,730 (2018)
Downloads

Latest articles

This journal has 61 open access articles

Journal updates

  • COVID-19 and impact on peer review

    As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

  • 2019 DDTR Best Paper of the Year

    Congratulations to the authors of Depletion of collagen by losartan to improve tumor accumulation and therapeutic efficacy of photodynamic nanoplatforms for winning the DDTR Best Paper of the Year award for 2019.


    New Content ItemSummary: It is critical to achieve efficient delivery of photosensitizers throughout the tumor sites in order to obtain therapeutically relevant photodynamic treatment (PDT) efficacy and desired clinical outcomes. However, synthesis and deposition of dense collagen in the tumor extracellular matrix (ECM) result in poor penetration and accumulation of photosensitizer within the tumor tissue. Herein, we develop a losartan pretreatment strategy to deplete tumor collagen, thereby improving the tumor accumulation and PDT efficacy of Chlorine 6 (Ce6) loaded periodic mesoporous organosilica (Ce6-PMO) photodynamic nanoplatform. After pretreatment with losartan in vivo, the tumor collagen I fraction in tumor tissue was significantly reduced by 53% and tumor uptake of Ce6-PMO subsequently administered via peritumoral and intravenous routes was remarkably enhanced. Further, combination of losartan and Ce6-PMO provided the best therapy efficacy, and the suppression rate of tumor volume was measured up to 82%. This study introduces a highly promising synergetic strategy to improve nanoplatform-based PDT efficacy for cancer therapy.

    This paper will be free to access until April 27, 2020.

  • CRS Nanomedicine and Nanoscale Delivery Focus Group Paper of the Year, 2019

    Congratulations to the authors of Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8+ T cell immune responses for being awarded Paper of the Year by the CRS Nanomedicine and Nanoscale Delivery Focus Group.


    New Content Item

    Summary: TumOpen in Tabor antigen-specific cytotoxic T lymphocytes (CTL) directly play a critical role in immunologic tumor inhibition and eradication. To address whether peptide nanovaccine could enhance specific CTL response, we established a syngeneic prostate cancer mouse model with TRAMP-C2  cells, followed by the treatments with either mouse six-transmembrane epithelial antigen of the prostate (mSTEAP) peptides emulsified in incomplete Freund’s adjuvant (IFA) via subcutaneous (SC) injection or nanovaccine carrying an identical amount of mSTEAP peptides via IV or SC injection. Meanwhile, the mouse models were treated with either CD8b mAb followed by nanovaccine treatment, free mSTEAP peptide, or empty PLGA nanoparticles. Immune responses in these mice were examined using cytotoxicity assays at 14 days after treatment. Tumor size and survival in various treatment groups were measured and monitored. The results demonstrated that mSTEAP peptide nanovaccine resulted in tumor inhibition by eliciting a significantly stronger CD8+ T cell immune response when compared with the controls. Moreover, the survival periods of mice treated with mSTEAP nanovaccine were significantly longer than those of mice treated with mSTEAP peptide emulsified in IFA or the treatment controls.
     

    This article will be free to access until May 11, 2020.

  • CRS Oral Drug Delivery Focus Group Paper of the Year, 2019

    The Oral Drug Delivery Focus Group of the Controlled Release Society has awarded the 2019 Paper of the Year award to the paper by Desai et al., Loratadine self-microemulsifying drug delivery systems (SMEDDS) in combination with sulforaphane for the synergistic chemoprevention of pancreatic cancer


    New Content Item Summary: Pancreatic cancer remains refractory to current standards-of-care. Here, we first report that combination of a classical antihistaminic drug, Loratadine (LOR), and a neutraceutical compound, Sulforaphane (SFN), elicits remarkably synergistic chemo-preventive action on pancreatic cancer cells in vitro. However, LOR belongs to BCS class II exhibiting low solubility and high permeability that results in poor oral bioavailability. To address this limitation, we have developed a self-microemulsifying drug delivery system (SMEDDS) formulation carrying LOR, using Quality by Design approach (globule size, 95.13 ± 7.9 nm; PDI, 0.17 ± 0.04), and confirmed that this nanoformulation provides significantly enhanced dissolution profile of LOR in vitro. Further, the nanoformulation, in conjunction with SFN, provided in ~ 7-fold and ~ 11-fold reduction in IC50 values compared to free drug LOR-SFN combination in MIA PaCa-2 and Panc-1 cell lines, respectively. Hence, our studies successfully demonstrate that a unique low-dose combination of LOR encapsulated within SMEDDS with SFN shows significantly enhanced chemo-preventive efficacy in pancreatic cancer.


    This paper will be free to access until May 5, 2020.

View all updates

Societies, partners and affiliations

Subscribe

  • Immediate online access
  • Full Journal access includes all articles
  • Downloadable in PDF
  • Subscription expires 12/31/2020

Advertisement

About this journal

Electronic ISSN
2190-3948
Print ISSN
2190-393X
Abstracted and indexed in
  1. CNKI
  2. Chemical Abstracts Service (CAS)
  3. EBSCO Discovery Service
  4. EMBASE
  5. Google Scholar
  6. Institute of Scientific and Technical Information of China
  7. Journal Citation Reports/Science Edition
  8. Medline
  9. Meta
  10. Naver
  11. OCLC WorldCat Discovery Service
  12. ProQuest-ExLibris Primo
  13. ProQuest-ExLibris Summon
  14. Reaxys
  15. SCImago
  16. SCOPUS
  17. Science Citation Index Expanded (SciSearch)
Copyright information

Rights and permissions

Springer policies

© Controlled Release Society